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Abstract
Background: Abuse of over-the-counter (OTC) products, such as diet pills and laxatives, for weight control by
adolescents is well-documented and can precipitate serious medical conditions. Yet only a small percentage of
youth with disordered weight control behaviors receive treatment. The objective of this study was to examine how
often clinicians communicate with youth with symptoms consistent with abuse of OTC products for weight control
about possible use of these products.
We used electronic medical records and administrative claims for services for 53,229 12 to 17 year old patients
receiving care from an integrated health system in the U.S. Northwest from August 2007 to December 2010. We
examined electronic text of clinical notes to identify encounters in which the clinician noted one of 10 metabolic
conditions potentially associated with abuse of OTC products (diet pills, laxatives, diuretics, ipecac, orlistat, and alli®)
for weight control and then assessed whether clinicians noted communication with adolescent patients about
possible use of OTC products for weight control.
Results: We identified 130 (0.2% of sample) patients with clinical notes indicating one or more of the metabolic
conditions. In clinical notes for only four (3.1%) of these patients did clinicians document suspicion or
communication about possible abuse of the OTC products. All four had a previous eating disorder diagnosis. In the
12 months subsequent to the clinical encounter in which a metabolic disturbance was identified, medical notes for
only three (2.3%) of the 130 patients indicated clinician suspicion or communication about possible abuse of these
products or an eating disorder.
Conclusions: Clinicians are missing a critical window of opportunity to query adolescents when presenting with
suspicious metabolic disturbances about possible abuse of OTC products for weight control. Clinicians may need
more training to detect OTC product abuse, and electronic medical records should prompt more thorough enquiry.
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Background
It is well-documented that adolescents abuse over-the-
counter (OTC) products such as diet pills, laxatives, and
diuretics in attempts to control their weight [1,2]. Esti-
mates from representative samples suggest 5.9% of female
and 4.2% of male U.S. high school students report using
diet pills without a physician’s orders in the past month
[2]. In a statewide representative sample of Minnesota
high school students, 1.9% of females and 1.7% of males
reported past-year laxative abuse for weight control [3].
Other studies with representative school-based samples of
adolescents have found in both males and females that
obese compared to nonoverweight youth reported higher
past-week prevalence of use of diet pills and laxatives for
weight control [4]; whereas, underweight males were more
likely and underweight females were less likely than same-
gender healthy weight youth to report use of diet pills,
laxatives, or vomiting for weight control [5]. Lifetime
prevalence of laxative abuse for weight control in the U.S.
general population is estimated to be 4% [6].
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can be serious and even life threatening [7]. The conse-
quences can include renal and hepatic failure, ischemic
and hemorrhagic stroke, cardiac arrhythmia, hypokalemia,
metabolic acidosis, and other electrolyte and fluid disor-
ders [8-14]. Despite the known health risks, OTC diet
pills, laxatives, and diuretics are widely available to youth
in pharmacies and online with almost no restrictions [15].
Even when there are restrictions, as with orlistat, which is
not approved for sale OTC to minors in the United States,
access is fairly unfettered [15].
No studies we are aware of have examined clinician
detection of OTC product abuse for weight control in
primary care settings or possible bias, such as related to
patient gender or weight status, in clinicians’ rate of de-
tection. There has been some relevant research, however,
on clinician detection practices and bias more broadly
related to eating disorders (of which abuse of OTC prod-
ucts for weight control may be a symptom) and mental
illness in general. The majority of youth with symptoms
of eating disorders do not receive treatment [16,17], and
underrecognition of eating disorder symptoms in clinical
settings is well-documented [18,19]. Gender disparities
in treatment access have been observed, where affected
boys are substantially less likely than girls with compa-
rable symptom severity to report receiving treatment
[17], and primary care physicians are less likely to detect
mental health problems in male than in female patients
[20]. Assumptions that eating disorders primarily affect
underweight individuals may also be a barrier to identifi-
cation of symptoms and treatment access in overweight
and healthy weight youth and adults [18,21,22].
Given that abuse of OTC products for weight control
can precipitate serious metabolic disturbances requiring
medical attention, the clinical encounter in which a youth
presents with such a condition is a potentially important
time to assess for OTC product use. Using a large medical
claims database, we examined how often clinicians docu-
mented communicating with youth with metabolic distur-
bances consistent with abuse of OTC products for weight
control about their possible use of these products. We hy-
pothesized that clinicians would rarely communiate about
abuse of these products with symptomatic patients. We
further hypothesized that among patients with a metabolic
disturbance, clinicians would be less likely to communi-
cate with boys than girls and more likely to communicate
with underweight than with other youth about abuse of
OTC products for weight control.
In an additional examination, we investigated how often
clinicians documented communicating with adolescent
patients generally, regardless of evidence of metabolic dis-
turbance, about use of OTC products for weight control.
Among adolescent patients in general, we hypothesized
that clinicians would be less likely to communicate with
boys than girls and more likely to communicate with
underweight than other youth about abuse of OTC prod-
ucts for weight control.
Methods
Group Health Cooperative is an integrated health system
in the U.S. Northwest serving approximately 640,000
members in Washington and Idaho. Group Health mem-
bers are generally similar to the area population in distri-
bution of age, sex, income, educational attainment, and
race/ethnicity. Members are enrolled through a mixture of
employer-sponsored insurance, individual insurance plans,
Medicare, Medicaid, and other subsidized insurance pro-
grams for low-income residents. Group Health provides
care through an internal group practice and a network of
contracted external providers. All group-practice, out-
patient facilities have used an electronic medical record
system (EpicCare, Epic Systems, Verona, WI) since 2005.
Our sample was restricted to enrollees seen by clinicians
at integrated group-practice locations because contracted
providers do not have access to the electronic medical rec-
ord. This study was approved by the institutional review
board of Group Health Cooperative.
We consulted with the research literature and expert
clinicians to identify a list of 10 types of metabolic distur-
bances that may be associated with OTC products abused
for weight control [7-13]. Using a combination of keyword
searches of clinical text and International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) codes (automated claims data), we identified all
instances of: electrolyte disturbance, hypochloremic alkal-
osis, hypermagnesmia, hypoalbuminemia, hypokalemia,
hyperchloremic acidosis, hyponatremia, hypophospatemia,
metabolic acidosis, and metabolic alkalosis.
We performed keyword searches of clinical text to
identify suspected or confirmed use of OTC products
for weight control. Our primary search terms included:
diet pills, laxatives, diuretics, ipecac, orlistat, and alli®.
Keywords were adapted using SAS “perl regular expres-
sions” [23] to capture encounters with misspelled key-
words. Each clinical note containing a reference to one
or more of the 10 selected metabolic disturbances or
potential use of weight loss products was reviewed indi-
vidually. Potential cases with negating language (e.g.,
“patient denies use of diet pills, laxatives, or diuretics”)
were coded as “suspected use.” Cases where clinicians
noted endorsement of product use for weight control
were coded as “confirmed use.”
Combined electronic medical records and administra-
tive claims for services were used to identify all encoun-
ters possibly associated with abuse of OTC products for
weight control. The full electronic text of clinical notes
from ambulatory, emergency department, telephone, and
secure electronic message encounters is downloaded
Austin et al. Journal of Eating Disorders 2013, 1:40 Page 2 of 7
http://www.jeatdisord.com/content/1/1/40from the electronic medical record to an indexed (search-
able) research database daily. We used this database to
search for encounters where the clinician noted or for-
mally diagnosed one or more of the 10 selected metabolic
disturbances (see list above). The keyword search of
clinical notes produced a list of unique patient identifica-
tion numbers. These identification numbers were used to
create a database of all clinical notes and health care
utilization (administrative claims) in the 12 months fol-
lowing the encounter at which a metabolic disturbance
was documented.
For secondary analyses, we also selected all clinical notes
of enrollees aged 12 to 17 years regardless of whether a
metabolic disturbance was documented to have occurred.
These notes were then flagged for any indication that the
clinician had suspicions or communicated about OTC
products for weight control.
Sample
Our sample included all Group Health enrollees aged 12
to 17 years continuously enrolled for at least 10 months
in any calendar year between Aug. 1, 2007, and Dec. 31,
2010. The study time frame corresponds to the earliest
date that clinical notes were assembled and indexed in
the research database. We excluded individuals from the
metabolic-disturbance population if they had one or
more medical conditions that would likely be associated
with the disturbances. We used ICD-9-CM diagnosis
codes to exclude anyone with a previous diagnosis of
renal disease, mitochondrial disorders, muscular dys-
trophy, hypertension, or any cancer. These diseases were
a basis for exclusion from our study because they and/or
their treatment can cause metabolic disturbances similar
to ones that can result from abuse of OTC products for
weight control [24-27]. We did not exclude individuals
with diabetes, as there is evidence that diabetic adoles-
cents are at elevated risk for disordered weight control
behaviors [28]. We did not exclude individuals with
diagnoses related to acute viral infections or gastrointes-
tinal problems; however, we did review notes individually
for evidence of these conditions as the primary reason
for the visit. Only one case needed to be eliminated due
to the clinician’s assessment of gastroenteritis (noted as
“viral syndrome”).
Statistical analyses
Height and weight, recorded in the clinical note within
30 days prior and subsequent to the patient presenting
with one or more of the selected metabolic disturbances,
were used to calculate body mass index (BMI) percentile
for age and sex following U.S. Centers for Disease Con-
trol and Prevention guidelines (http://www.cdc.gov/
growthcharts/). Youth were then assigned weight status
categories based on their BMI percentile as follows:
overweight/obese: BMI ≥ 85th; healthy weight: 15th ⪯
BMI <85th; underweight: BMI<15th.
Among youth with one or more metabolic disturb-
ance, Pearson Chi-square tests were used to examine for
possible gender differences age, weight status, previous
eating disorder diagnosis, and type of metabolic disturb-
ance identified. While additional Chi-square tests had
been planned to assess gender differences in clinician
suspicion of OTC product use for weight control, patient
denial of use, and patient endorsement of use, there
were not sufficient cases to conduct statistical analyses
of gender differences in these outcomes.
Among the sample of youth with a clinical note that
included one of the OTC product terms included in our
search, regardless of presence of a metabolic disturb-
ance, we used Chi-square tests to examine for possible
gender differences in clinician suspicion of OTC product
use for weight control, patient denial of use, and patient
endorsement of use, and previous eating disorder diagno-
sis. Pearson Chi-square tests were also used to examine
for possible weight-status group differences in clinician
communication about use of an OTC product for weight
control. All analyses were performed with the statistical
package SAS 9.2.
Results
Our sample included 53,229 youth (26,015 females and
27,214 males) ages 12 to 17 years enrolled in Group
Health Cooperative during the 29-month observation
period. We identified 130 (0.2% of sample; 77 females
and 53 males) patients with clinical notes indicating one
or more of the selected metabolic disturbances. Based
on 230 clinical notes from these 130 patients, Table 1
displays the sex, age, weight status, any eating disorder
diagnosis, and type of metabolic disturbances noted for
these patients. In medical notes for only four (3.1%) pa-
tients did the clinician document communication about
possible abuse of the products during the encounter in
which the disturbance was reported, and all four had a
previous eating disorder diagnosis. In addition, in the
12 months subsequent to the clinical encounter in which
a metabolic disturbance was noted, the medical notes
for only three (2.3%) of the 130 patients documented
that clinicians communicated about possible abuse of
these products or an eating disorder.
In secondary analyses, results of our search for specific
product terms (diet pills, laxatives, diuretics, ipecac,
orlistat, and alli®), regardless of the presence or absence
of a metabolic disturbance, are presented in Table 2. We
identified 745 notes that included one or more of these
search terms for 426 (0.8% of total sample) youth. By
gender, we identified 588 notes for 307 females (1.2% of
female sample) and 157 notes for 119 males (0.4% of
male sample). In the 745 notes, clinicians documented
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44 notes (5.9% of notes) and documented patient denial
of use in 396 notes (53.2% of notes). Of the 426 youth,
12.4% (n= 53, all females) reported use of one or more
of the products; almost 95% of admitted use was of laxa-
tives and the remainder diet pills.
Examining patterns by patient gender, we found that
among the 426 youth with a note that included one of
the OTC product terms used in our search, clinicians
were more likely to document communicating with fe-
male than male patients, either by recording the patient
endorsed use or denied use (P’s<0.0001), though we did
not find a difference by patient gender in clinicians not-
ing suspicion of use (P= 0.51).
Table 3 shows patterns by adolescent weight status
within the 745 clinical notes. We found that while more
than 80% of notes for underweight youth indicated clini-
cians communicated with patients (either by recording
the patient endorsed use or denied use) about use of
OTC products for weight control, just over 40% of notes
for overweight and obese youth indicated their clinicians
communicated with them about use of these products
(P <0.0001 for difference across weight categories).
Discussion
To our knowledge, ours is the first large-scale study to
evaluate the frequency and patterns of clinicians com-
municating with youth about possible abuse of OTC
products for weight control. Findings suggest clinicians
rarely note suspicion or communication about the use of
these products and likely are missing indicators of pos-
sible abuse of OTC products for weight control. Though
self-report survey data from representative community-
based samples estimate more than 5% of U.S. adoles-
cents abuse OTC products for weight control each
month, in our study of over 53,000 adolescent patients’
records, only 0.8% of patients’ notes documented suspi-
cion or communication about these products. Even
when patients presented with suspicious metabolic dis-
turbances, such as hypokalemia and hyponatremia, very
Table 1 Selected characteristics documented in 230
clinical notes for 130 adolescent patients (77 females and
53 males) ages 12-17 years presenting with a metabolic
disturbance potentially associated with abuse of over-








Mean age, years (std. dev) 15.5 (1.48) 15.5 (1.56) 0.8979
Weight status
c, % (n)
Underweight 16.9 (13) 22.6 (12) 0.049
Healthy weight 52.0 (40) 30.2 (16)
Overweight 15.6 (12) 15.1 (8)
Obese 15.6 (12) 32.1 (17)
Any previous eating disorder
diagnosis, % (n)
7.8 (6) 3.8 (2) 0.349
Type of condition noted
d,
% (n)
Electrolyte disturbance 8.2 (12) 8.3 (7) 0.976
Hypochloremic alkalosis 0 0 N/A
Hypermagnesmia 0 0 N/A
Hypoalbuminemia 6.2 (9) 2.4 (2) 0.195
Hypokalemia 0 0 N/A
Hyperchloremic acidosis 0 0 N/A
Hyponatremia 0 0 N/A
Hypophospatemia 1.4 (2) 2.4 (2) 0.572
Metabolic acidosis 7.5 (11) 8.3 (7) 0.820
Metabolic alkalosis 4.8 (7) 3.6 (3) 0.661
aData are aggregated from 230 notes over a 29-month observation period
from Aug. 1, 2005, through Dec. 31, 2010.
bP-value from Pearson Chi-square test of gender differences.
cWeight status categories defined according to BMI percentile for age and sex
as follows: obese: BMI≥ 95th; overweight: 95th > BMI ≥85th; healthy weight:
15th ≤ BMI < 85th; underweight: BMI < 15th.
dPatients could be diagnosed with more than one metabolic disturbance.
Table 2 Selected characteristics documented in 745 clinical notes for 426 adolescent patients (307 females and 119




(N=588 Notes) (N= 157 Notes)
Mean age, years (std. dev.) 15.1 (1.6) 14.8 (1.6) 0.0031
Clinician notes suspicion of use of OTC products abused for weight control, % (n) 5.6 (33) 7.0 (11) 0.51
Patient denies use of OTC products abused for weight control (negating language
used by clinician), % (n)
60.5 (356) 25.5 (40) <0.0001
Patient endorses use, % (n) 9.0 (53) 0.0 (0) <0.0001
Any previous eating disorder diagnosis, % (n patients) 29.0% (n=89 cases/307
patients)
8.4% (n =10 cases/119
patients)
<0.0001
a Data are aggregated from 745 notes over a 29-month observation period from Aug. 1, 2005, through Dec. 31, 2010.
b P-value from Pearson Chi-square test of gender differences.
Austin et al. Journal of Eating Disorders 2013, 1:40 Page 4 of 7
http://www.jeatdisord.com/content/1/1/40few notes indicated any clinician attention to possible
OTC product abuse. Out of 130 youth presenting with
suspicious metabolic disturbances, only four had records
indicating the clinician communicated with the patient
about possible abuse of OTC products for weight con-
trol at the time the disturbance was identified. All four
of these adolescents had a previous eating disorder diag-
nosis, suggesting that the previous diagnosis, rather than
the metabolic disturbance alone, might have prompted
clinician attention.
Our study was in part designed to examine differences
in clinician communication practices associated with pa-
tient gender and weight status among youth presenting
with metabolic disturbances. Because so few patients
with metabolic disturbances were queried, we were un-
able to conduct statistical tests to compare patterns
within youth with these disturbances.
In secondary analyses, we identified youth whose clinical
note included mention of OTC product terms used in our
search, regardless of presence or absence of a metabolic
disturbance. In support of our hypothesis about gender
bias in clinician communication practices, we found a 3:1
(i.e., 1.2:0.4) female-to-male gender ratio in the prevalence
of clinicians documenting communicating with patients
regarding OTC products used for weight control. This
gender ratio should be considered in light of results from
representative, community-based research mentioned
above, which estimates the female-to-male ratio in past-
month diet pill use as approximately a 1.4:1 [2]. Our
finding is consistent with prior research documenting pri-
mary care physician underrecognition of mental health
problems in men compared to women patients [20]. In
addition, our findings suggest clinician gender bias in
communication practices may in part explain the results
of another study documenting that when adolescent boys
and girls with commensurate eating disorders symptom
severity were compared, boys were much less likely than
girls to have ever received treatment for their symptoms
[17]. In contrast to our hypotheses, however, we found no
difference by patient gender in clinician documentation of
suspicion of use.
In addition, we found an inverse gradient of communi-
cation about OTC products associated with patient weight
status, where the prevalence of documented clinician
communication was highest among underweight youth
and lowest among overweight and obese youth. This find-
ing provides support for our hypothesis regarding weight-
related bias in clinician communications and is consistent
with prior research that eating disorder symptoms are
underrecognized in clinical settings, especially among
overweight and obese individuals who may be offered
treatment for their weight but not for their underlying eat-
ing disorder symptoms [18,21,29].
Our study has several limitations. One, data were gath-
ered from extensive electronic medical records and ad-
ministrative claims for services; however, clinical notes
may be incomplete because providers may not document
all communications with patients for a variety of reasons,
including time pressure in the clinical visit and concerns
about confidentiality if providers believe parents or care-
givers may have access to their minor child’s electronic re-
cords. Providers may do a complete review of systems,
asking questions about weight control methods, yet docu-
ment the communication only as a negative review of
systems. As incomplete documentation has been a long-
standing concern within healthcare systems generally
[30-32], Group Health offers regular trainings for pro-
viders and conducts coding audits to improve quality and
completeness of documentation of clinical encounters.
Two, it was not possible to determine how many of the
patients abused OTC products for weight control, as re-
cords capture only those whose clinicians documented
both asking patients and the patients’ response. Further-
more, patients who use OTC products may deny use
when asked in an effort to conceal stigmatized behavior
[33]. Three, our search terms were deliberately inclusive
with the goal of capturing all clinician notes related to
OTC products used for weight control, yet it is possible
some clinicians used different terms in their notes when
communicating about these products. Four, while we
found evidence to support our hypotheses regarding clin-
ician bias in communication practices associated with
patient gender and weight status, we were not able to
examine the other possible types of clinical bias, such as
bias related to patient race/ethnicity or socioeconomic
position, as has been observed in other studies [34-37].
Five, we excluded patients who had been diagnosed with
major illnesses in which the disease or its treatment may
cause metabolic disturbances; however, in some cases,
providers may have reasonably assumed the observed
metabolic disturbances were explained by another known
Table 3 Documentation of clinician communication about
use of OTC products for weight control in clinical notes
by weight status for 426 adolescent patients (307






c, % (n) Yes No <0.0001
Underweight (notes= 273) 81.3 (222) 18.7 (51)
Healthy weight (notes= 346) 63.0 (218) 37.0 (128)
Overweight (notes=71) 42.3 (30) 57.7 (41)
Obese (notes=55) 41.8 (23) 58.2 (32)
a Data are aggregated from 745 notes over a 29-month observation period
from Aug. 1, 2005, through Dec. 31, 2010.
b P-value from Pearson Chi-square test of weight-status group difference.
c Weight status categories defined according to BMI percentile for age and sex
as follows: obese: BMI≥ 95th; overweight: 95th > BMI ≥85th; healthy weight:
15th ∩ BMI < 85th; underweight: BMI < 15th.
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products. That said, when we individually reviewed
notes for patients with metabolic disturbances, we
found only one case in which the clinician documented
a gastroenteritis-like condition, specifically noting “viral
syndrome.”
Survey research with U.S. adolescent girls and boys
has well-documented abuse of OTC products for weight
control. Representative, community-based research has
estimated that more than 5% of youth report past-
month use of OTC products for weight control, such as
diet pills, laxatives, and diuretics [2]. Only a small per-
centage of youth with these and other eating disorder
symptoms receive treatment [16,17], which may in part
relate to our finding that clinicians rarely communicate
about abuse of these products. Though abuse of OTC
products for weight control can precipitate serious con-
ditions requiring medical attention [7-14], they are
widely and easily available to youth in pharmacies and
online [15]. One important strategy proposed to reduce
the harm these products pose to young people is to im-
pose age restrictions on purchases [15]. Clinicians can
also play an important role given that they are in a
unique position to recognize signs and symptoms of
OTC product abuse in patients and to help these youth
adopt more healthful behaviors related to weight and
shape.
Conclusion
Clinical encounters in which a youth presents with a
metabolic disturbance consistent with abuse of OTC
products for weight control may be a critical window for
clinicians to screen for this behavior and intervene if
needed. Our findings suggest clinicians may need more
training in recognizing symptoms of abuse of OTC prod-
ucts for weight control. In addition, the electronic medical
record could be a useful tool in reminding clinicians to
enquire about weight control products, especially for pa-
tients with eating disorder diagnoses or who present with
an unexplained metabolic disturbance, by adding into the
template prompts regarding communication on use of
these products. It is worth noting that the majority of
patients using these products may not present with sub-
stantial metabolic disturbance, as these problems are most
likely to arise primarily in heavy users [9,10,38]. More
thorough clinical enquiry is warranted about possible
abuse of OTC products for weight control with both
female and male adolescents as a whole across the weight-
status spectrum in addition to those presenting with sus-
picious metabolic disturbances.
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